Literature DB >> 30074178

Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.

Yan-Xiang Cheng1, Gan-Tao Chen2,3, Xiao Yang1, Yan-Qing Wang1, Li Hong4.   

Abstract

The objectives of this study were to investigate the effects of the CRISPR/Cas9 system mediated by the HPV pseudotype virus on SiHa cytobiology behavior by cutting the HPV16 E6 gene selectively and to explore the role of this system in the treatment of cervical cancer. After designing specific gRNA sequences targeting HPV16 E6, generating hCas9-EGFP and E6-gRNA-RFP plasmids, and preparing the pseudovirus of HPV16 carrying E6-gRNA and Cas9 plasmids, we determined the titer of the pseudotype virus using the TCID50 method. We obtained the pseudotype virus of HPV16 carrying E6-gRNA and Cas9 plasmids to transfect cervical cancer SiHa cells. Experimental subjects were divided into control group, empty virus group, E6-gRNA transfected group, Cas9 transfected group and Cas9+E6-gRNA transfected group. The molecular size of the cutting sequence was detected using the T7E1 enzyme digestion method and agarose gel electrophoresis, and the cleavage function of CRISPR/Cas9 on the E6 gene was determined at the same time. RT-PCR and Western blotting were performed to detect the mRNA and protein expression levels of E6 in all the groups; the Transwell cell migration assay was performed to detect the cell migration ability and metastasis in all groups. Heterotopic transplantation tumors were incorporated into mice and were used to investigate the effects of the CRISPR/Cas9 system mediated by the HPV pseudovirus on the tumorigenic ability of SiHa cells by selectively cutting HPV16 E6. The HPV16 pseudotype virus carrying E6-gRNA and Cas9 plasmids could successfully infect SiHa cells, and there were two cutting zones in the Cas9+E6-gRNA transfected group. However, the empty virus group, E6-gRNA transfected group and Cas9 transfected group had no corresponding zone. Compared with those in the control group, the empty virus group, E6-gRNA transfected group and Cas9 transfected group, the mRNA and protein expression levels of E6 in SiHa cells were downregulated in the Cas9+E6-gRNA transfected group (P<0.01). In addition, the proliferation and migration abilities of SiHa cells were significantly inhibited (P<0.01). There were no significant differences among the other groups. In contrast to the control group, the HPV pseudotype virus carrying E6-gRNA and Cas9 plasmids could significantly delay the growth of tumor cells of the ectopic tumor transplantation model (P<0.01). The CRISPR/Cas9 system mediated by the HPV pseudotype virus to knockout E6 gene expression exhibited a clear inhibitory effect on the biological function of SiHa cells, which indicated that knocking out the E6 gene using the CRISPR/Cas9 system mediated by the HPV pseudotype virus had a potential effect of eliminating HPV infection and inhibiting the growth of HPV-related tumors. Taken together, these findings provide insight into a new treatment strategy for the prevention and treatment of hr-HPV infected disease, particularly in HPV-related tumors.

Entities:  

Keywords:  CRISPR/Cas9; E6 gene; HPV pseudotype virus; cervical cancer

Mesh:

Substances:

Year:  2018        PMID: 30074178     DOI: 10.1007/s11596-018-1868-3

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  33 in total

1.  Correlation between physical status of human papilloma virus and cervical carcinogenesis.

Authors:  Kezhen Li; Xin Jin; Yong Fang; Changyu Wang; Mei Gong; Pingbo Chen; Jia Liu; Dongrui Deng; Jihui Ai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 2.  Lentiviruses as gene transfer agents for delivery to non-dividing cells.

Authors:  L Naldini
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

3.  DNA-guided genome editing using the Natronobacterium gregoryi Argonaute.

Authors:  Feng Gao; Xiao Z Shen; Feng Jiang; Yongqiang Wu; Chunyu Han
Journal:  Nat Biotechnol       Date:  2016-05-02       Impact factor: 54.908

4.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

5.  DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.

Authors:  Peter Melsheimer; Svetlana Vinokurova; Nicolas Wentzensen; Gunther Bastert; Magnus von Knebel Doeberitz
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

Review 6.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

7.  CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool.

Authors:  Manuel Stemmer; Thomas Thumberger; Maria Del Sol Keyer; Joachim Wittbrodt; Juan L Mateo
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

8.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

9.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.

Authors:  Dirk Heckl; Monika S Kowalczyk; David Yudovich; Roger Belizaire; Rishi V Puram; Marie E McConkey; Anne Thielke; Jon C Aster; Aviv Regev; Benjamin L Ebert
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

10.  Transcriptional repression of E-cadherin by human papillomavirus type 16 E6.

Authors:  Zarina J D'Costa; Carol Jolly; Elliot J Androphy; Andrew Mercer; Charles M Matthews; Merilyn H Hibma
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.